Genmab — September 2025

[E_L]

As of June 30, 2025, Merus had $892 million cash, cash equivalents and marketable securities.

[Dusør]

Super med en offensiv indstilling i et presset marked. Kender ikke firmaet, men priserne på biotek er i bund . Godt tidspunkt at bruge sine midler til vækst.

[Solsen]

Merus har et meget spændende stof i head and neck. Stoffet har read out på to fase 3 næste år. Så 2026 bliver det store read out år

[E_L]

yeah, it was one of the most prominent news at ASCO
https://www.oncologypipeline.com/apexonco/asco-2025-preview-merus-tops-bicara

[E_L]

ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer https://finance.yahoo.com/news/asco-2025-merus-wins-head-105450309.html

[lahn1]

Så slutter vores positive up trend. Det er slut med at prale af ingen gæld tvært imod blive Gmab nu et meget gælds tynget selskab men en financial leverage på > 5 Det skal nok blive godt på den lamge bane men øv for trenden hvis jeg ikke tager meget fejl.

[royal]

Håber du tager fejl.

[E_L]

it does put some additional perspective on why some early clinical trials were deemed not good enough to proceed

[nohope]

Vil undre mig meget hvis det ikke koster dyrt på kursen.

[lahn1]

Yes EL that was rettidigt omhu, as we say kn Denmark.

[lahn1]

It sures raises some attention to Gmab with this size of M&A. And with the very succesfull Profound deal in the bag, hopefully market will trust Gmab judgement this time.

[BuyLow]

The offices of Merus and Genmab are next to each other in Utrecht. They know each other well. GMAB has 3Bn cash, earning 1Bn a year, rising to 1,5Bn per year
in 2028. They can easily fund the debt based on recurring cashflow.

[E_L]

they are actually in the same building...

[E_L]

14/10 09:24
af E L
The new building next to the (also rather new...) Genmab R&D Center in Utrecht was opened. it will house Genmab, Merus and ImmunoPrecise Antibodies https://vastgoedberichten.nl/2023/10/13/kadans-opent-innovatiecentrum-accelerator-utrecht-op-utrecht-science-park/

[lahn1]

Have we heard anything from the IPA collaboration ?

[lahn1]

Markedet er meget uenige om

[Solsen]

Det bør koste på kursen pga af størrelsen af købet.

[Solsen]

Genmab skal for første gang gældsætte sig eller sælge aktier for at finansiere købet.

[nohope]

I bedste fald er udbytte eller tilbagekøb udskudt mindst 5 år.

[transalp]

Men tror vi på genmab, er det jo mere menig i udvidelse, snare end udbytte og tilbagekøb. Men giver en lille trækning, når man tænker på fabrikken i USA..